Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(ω-carboxyalkyloxy)benzyl]pyrimidines: Marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim

Journal of Medicinal Chemistry

Volumn 45, Issue 1, 2002, Pages 233-241

  Rosowsky, A ^a   Forsch, R A ^a   Queener, S F ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 (2 METHOXY 5 HEPTYLOXYBENZYL)PYRIMIDINE; 2,4 DIAMINO 5 (2 METHOXY 5 HEXYLOXYBENZYL)PYRIMIDINE; 2,4 DIAMINO 5 (2 METHOXY 5 NONYLOXYBENZYL)PYRIMIDINE; 2,4 DIAMINO 5 (2 METHOXY 5 OCTYLOXYBENZYL)PYRIMIDINE; 2,4 DIAMINO 5 (2 METHOXY 5 PENTYLOXYBENZYL)PYRIMIDINE; 2,4 DIAMINO 5 [(2 METHOXY 5 (3 CARBOXYPROPYLOXY)BENZYL]PYRIMIDINE; 2,4 DIAMINO 5 [(2 METHOXY 5 (4 CARBOXYBUTYLOXY)BENZYL]PYRIMIDINE; 2,4 DIAMINO 5 [(2 METHOXY 5 (5 CARBOXYPENTYLOXY)BENZYL]PYRIMIDINE; 2,4 DIAMINO 5 [(2 METHOXY 5 (6 CARBOXYHEXYLOXY)BENZYL]PYRIMIDINE; 2,4 DIAMINO 5 [(2 METHOXY 5 (7 CARBOXYHEPTYLOXY)BENZYL]PYRIMIDINE; DIHYDROFOLATE REDUCTASE INHIBITOR; PIRITREXIM; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; MYCOBACTERIUM AVIUM; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII;

ANIMALS; FOLIC ACID ANTAGONISTS; LIVER; MYCOBACTERIUM AVIUM; PNEUMOCYSTIS; PYRIMIDINES; RATS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; TRIMETHOPRIM;

EID: 0037011908     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010407u     Document Type: Article

References (55)

1. Drug treatment of HIV-related opportunistic infections
2. Safety and efficacy of sulfamethoxazole and trimethoprim prophylaxis for Pneumocystis carinii pneumonia in AIDS
3. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone
4. Comparison of atovaquone ((566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS
5. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsonetrimethoprim, and clindamycin-primaquine
6. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients
7. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV
8. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
9. Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine
10. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase
11. A phase II study of piritrexim in patients with advanced squamous head and neck cancer
12. Oral piritrexim-a phase II study in patients with advanced soft tissue sarcoma
13. Chemotherapy for advanced bladder cancer
14. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder
15. Piritrexim wit leucovorin for the treatment of pneumocystis pneumonia (PCP) in AIDS patients
16. Dihydrofolate reductase as a therapeutic target
17. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: Potential for screening therapeutic agents
18. Adverse cutaneous reactions to trimethoprimsulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia
19. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole associated Pneumocystis carinii pneumonia
20. Potent antipneumocystis and antitoxoplasma activities of piritrexim, and lipid-soluble antifolate
21. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs
22. Identification of highly potent and selective inhibitor of Toxoplasma gondii dihydrofolate reductase
23. Synthesis and antiparasitic and antitumor activity of 2,4-diamino-5-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim
24. The structure of mouse L1210 dihydrofolate reductase-drug complexes and the construction of a model of human enzyme
25. Preliminary crystallographic data for Pneumocystis carinii dihydrofolate reductase
26. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 Å resolution
27. High-affinity inhibitors of dihydrofolate reductase: Antimicrobial and anticancer activities of 7,8-dialky11,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size
28. Tuberculosis and HIV infection: A global perspective
29. Dual pulmonary infection with Mycobacterium tuberculosis and Pneumocystis carinii in patients infected with human immunodeficiency virus
30. In vitro and in vivo results of brodimoprim and analogues alone and in combination against E. coli and Mycobacterium
31. Prophylactic effect of co-trimoxazole for Mycobacterium avium complex infection: A previously unreported benefit
32. Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex
33. In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex
34. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophiIic deazapteridine derivatives, inhibitors of dihydrofolate reductase
35. Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase
36. Selective formylation of diphenols
37. 2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 5. 3′,5′-Dimethoxy-4′-substituted benzyl analogues of trimethoprim
38. 2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 6. A one-step synthesis of new trimethoprim derivatives and activity analysis by molecular modeling
39. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene
40. Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii
41. Heterologous expression and characterization of the bifunctional dihydrofolate reductase-thymidylate synthase enzyme of Toxoplasma gondii
42. Identification and cloning of the Mycobacterium avium folA gene, required for dihydrofolate reductase activity
43. Epiroprim
44. Activity of epiroprim (Ro11-8958) alone and combination with dapsone against Toxoplasma gondii
45. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice
46. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone
47. New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii
48. 2,4-Diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective inhibitors of dihydrofolate reductases
49. Receptor-based design of dihydrofolate reductase inhibitors: Comparison of crystallographically determined enzyme-binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues
50. Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase
51. Conformationally restricted analogues of trimethoprim: 2,6-Diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii
52. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: Design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines
53. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations
54. Structure-based design of selective inhibitors of dihydrofolate reductase: Synthesis and antiparasitic activity of 2,4-diaminopteridine analogues with a bridged diarylamine side chain
55. Isotope exchange and solvolysis in the basic methanolysis of aryl esters. Molecular interpretation of free energies, enthalpies, and entropies of activation